US 11,701,406 B2
Combination of low dose IL-2 and an inhibitor of Treg IL-2R desensitization to treat autoimmune and allergic inflammatory diseases
C. Garrison Fathman, Stanford, CA (US); and Luis R. Soares, Stanford, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Appl. No. 16/614,626
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
PCT Filed May 25, 2018, PCT No. PCT/US2018/034591
§ 371(c)(1), (2) Date Nov. 18, 2019,
PCT Pub. No. WO2018/218119, PCT Pub. Date Nov. 29, 2018.
Claims priority of provisional application 62/511,002, filed on May 25, 2017.
Prior Publication US 2021/0379155 A1, Dec. 9, 2021
Int. Cl. A61K 38/20 (2006.01); A61P 37/06 (2006.01); A61P 3/10 (2006.01); A61K 31/352 (2006.01); A61K 31/428 (2006.01); A61K 31/4365 (2006.01); A61K 31/4468 (2006.01); A61K 31/451 (2006.01); A61K 31/496 (2006.01); A61K 31/498 (2006.01); A61K 31/519 (2006.01); A61K 31/538 (2006.01); A61K 31/7064 (2006.01); A61K 31/7076 (2006.01)
CPC A61K 38/2013 (2013.01) [A61K 31/352 (2013.01); A61K 31/428 (2013.01); A61K 31/4365 (2013.01); A61K 31/4468 (2013.01); A61K 31/451 (2013.01); A61K 31/496 (2013.01); A61K 31/498 (2013.01); A61K 31/519 (2013.01); A61K 31/538 (2013.01); A61K 31/7064 (2013.01); A61K 31/7076 (2013.01); A61P 3/10 (2018.01); A61P 37/06 (2018.01)] 14 Claims
 
11. A method for treating an inflammatory disease in a subject in need thereof, comprising administering to the subject:
(i) an effective dose of NEDD8 activating enzyme (NAE) inhibitor

OG Complex Work Unit Chemistry
(ii) a low dose of IL-2 of from 0.05×106 IU/m2 to 5×106 IU/m2;
thereby increasing or restoring function of regulatory T lymphocytes (Tregs) and treating the inflammatory disease.